Pure Global
NCT06227845

Preterm Infant Intestinal Microbiota Development and Maternal Fecal Transplant

Otto Helve·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Microbial Colonization
Drug/Device/Intervention
Fecal microbiota transplant
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Otto Helve
Funder
Helsinki University Central Hospital
Location
Helsinki, Finland
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2024
End date
Dec 01, 2026
Enrollment
36 participants
Primary outcome

Safety; Incidence of Treatment- Adverse Events eg. infections and increased need for respiratory support

Summary

The goal of this clinical trial is to study if a oral maternal fecal transplant given to a
 premature infant born by cesarean section (CS) is safe. The investigators will also compare
 the gut microbiome of the infants to those born by CS and not received the transplant and to
 premature infants born vaginally.

ICD-10 classifications
Bacterial infection of unspecified siteOther bacterial infections of unspecified siteBacterial, viral and other infectious agentsCholeraOther specified bacterial intestinal infections
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06227845
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06227845 through Pure Global AI's free database. This phase not specified trial is sponsored by Otto Helve and is currently Not yet recruiting. The study focuses on Microbial Colonization. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.